Interneuron Pharmaceuticals
Executive Summary
Cambridge, Massachusetts based neurological R&D start-up making initial public offering of 1 mil. units at anticipated price of $5 per unit. Each unit consists of three common shares and three redeemable Class A warrants. D. H. Blair, which provided first funding for firm in October 1988, is underwriting offer. Interneuron's lead compound is the glycine mediator threonine which the company hopes to develop as an orphan drug for familial spasticity ("The Pink Sheet" March 27, T&G-7).